FDA ApprovedUnited States
New Treatment for a Rare Blood Cancer (BPDCN) in Adults
Decnupaz (pivekimab sunirine-pvzy) — CD123 ADC for adults with BPDCN
FDA approval on 27 May 2026 for Decnupaz (pivekimab sunirine-pvzy) — a CD123-directed antibody and alkylating-agent conjugate — for adults with blastic…
This is for adults with BPDCN — an ultra-rare, aggressive blood/bone-marrow cancer that often involves skin, marrow, nodes, and other organs — who may be…